It's honor to me to contact you Prof. Giovina Ruberti.
My name is Ahmed Mohsen Kamal, I'm a demonstrator at medicinal chemistry department-faculty of pharmacy-Assiut university-Egypt
I'm working on synthesis new norfloxacin derivatives with possible antibacterial, antimycobacterial and anticancer activity. My new compounds were exposed to in-silico studies through molecular modelling and showed promising activity on histone deacetylase enzyme more than norfloxacin and SAHA. I wonder if there's any possibility to cooperate with you prof and make screening for my new compounds to determine their anticancer activity and their inhibitory effect on histone deacetylase enzyme.
I have attached an excel spreadsheet with the results so far. We have all MICs against E. coli. There are several compounds with quite a good MIC, two with an MIC comparable to Nor, and one with an even better MIC. We have tested all compounds against P. aeruginosa. Less of them are active, but we have at least three with an MIC ≤ 1, which we will test again together with Nor and Cip.
We have done mode of action confirmation for gyrase in E. coli, where we selected the best compounds of each series, 19 in total. 18 of those show a phenotype consistent with gyrase inhibition. We have tested off-target activity on the inner membrane of E. coli and none of the 19 tested compounds showed any effects.
Next week, we plan to test outer membrane activity in E. coli with the best representative of each series. M. tuberculosis is still growing slowly. We will wait until the cultures are ready to complete the MIC assays (and we do not have 96-well plates at the moment because Covid testing has depleted the supply in Sweden, so we have to wait for that, too). Once Mtb is in log phase and we have the plates, we will test MICs against Mtb, test lower concentrations of the three best compounds against P. aeruginosa, and test S. aureus as well.
After that, we will test the best compounds against quinolone-resistant P. aeruginosa and S. aureus. Then we will test effects on peptidoglycan synthesis in Gram-positives with the compounds that are most active against S. aureus. So that is the plan. Unfortunately, I cannot tell you exactly when Mtb will be ready and when we will have plates again, but I made an estimate in the excel file. I will send you updated versions of the spreadsheet when results come in. 
It's honor to me to contact you Prof.  
Giovina
  Ruberti
.
My name  
is Ahmed
  Mohsen
 Kamal, I'm a demonstrator at medicinal chemistry department-faculty of  
pharmacy-Assiut
 university-Egypt
I'm working on synthesis new  
norfloxacin
 derivatives with possible antibacterial,  
antimycobacterial
 and anticancer  
activity
. My new compounds  
were exposed
 to  
in-silico
 studies through molecular modelling and  
showed
 promising  
activity
 on histone  
deacetylase
 enzyme more than  
norfloxacin
 and  
SAHA
. I wonder if there's any possibility to cooperate with you prof and  
make
 screening for my new compounds to determine their anticancer  
activity
 and their inhibitory effect on histone  
deacetylase
 enzyme.
I have attached an  
excel
 spreadsheet with the results  
so
 far. We have all  
MICs
 against E. coli. There are several compounds with quite a  
good
 MIC, two with an MIC comparable to Nor, and one with an even better MIC. We have  
tested
 all compounds against P.  
aeruginosa
. Less of them are active,  
but
 we have at least three with an MIC ≤ 1, which we will  
test
 again together with Nor and  
Cip
.
We have done mode of action confirmation for  
gyrase
 in E. coli, where we selected the  
best
 compounds of each series, 19 in total. 18 of those  
show
 a phenotype consistent with  
gyrase
 inhibition. We have  
tested
 off-target  
activity
 on the inner membrane of E. coli and none of the 19  
tested
 compounds  
showed
 any effects. 
Next
 week, we plan to  
test
 outer membrane  
activity
 in E. coli with the  
best
 representative of each series. M. tuberculosis is  
still
 growing  
slowly
. We will wait until the cultures are ready to complete the MIC assays (and we do not have 96-well plates at the moment  
because
  Covid
 testing has depleted the supply in Sweden,  
so
 we  
have to
 wait for that, too). Once  
Mtb
 is in log  
phase and
 we have the plates, we will  
test
  MICs
 against  
Mtb
,  
test
 lower concentrations of the three  
best
 compounds against P.  
aeruginosa
, and  
test
 S. aureus  
as well
.
After that, we will  
test
 the  
best
 compounds against  
quinolone-resistant
 P.  
aeruginosa
 and S. aureus. Then we will  
test
 effects on peptidoglycan synthesis in Gram-positives with the compounds that are most active against S. aureus.  
So
  that is
 the plan. Unfortunately, I cannot  
tell
 you exactly when  
Mtb
 will be ready and when we will have plates again,  
but
 I made an estimate in the  
excel
 file. I will  
send
 you updated versions of the spreadsheet when results  
come
 in.